scispace - formally typeset
A

Aoi Masuda

Researcher at Universidade Federal do Rio Grande do Sul

Publications -  54
Citations -  2238

Aoi Masuda is an academic researcher from Universidade Federal do Rio Grande do Sul. The author has contributed to research in topics: Rhipicephalus & Rhipicephalus microplus. The author has an hindex of 29, co-authored 54 publications receiving 2037 citations.

Papers
More filters
Journal ArticleDOI

In vitro assessment of Metarhizium anisopliae isolates to control the cattle tick Boophilus microplus

TL;DR: Isolates of M. anisopliae taken from experimentally infected ticks proved to be more pathogenic than fungus maintained on culture media and suggested that, in general, virus free isolates were more infective.
Journal ArticleDOI

Isolation of an aspartic proteinase precursor from the egg of a hard tick, Boophilus microplus

TL;DR: Western blot analysis using anti-BYC monoclonal antibodies showed proteolytic processing of BYC during embryogenesis and suggested activation of the enzyme during development, and a role of BYc in degradation of vitellin, the major yolk protein of tick eggs, is discussed.
Journal ArticleDOI

Cloning and functional expression of a Boophilus microplus cathepsin L-like enzyme.

TL;DR: A cysteine proteinase gene homologous to cathepsins L genes was isolated from a B. microplus cDNA library and its optimal enzymatic activity on both fluorogenic and protein substrates was found to occur at an acidic pH.
Journal ArticleDOI

ABC transporter efflux pumps: a defense mechanism against ivermectin in Rhipicephalus (Boophilus) microplus.

TL;DR: The ability of ABC transporter inhibitors to enhance ivermectin (IVM) sensitivity was tested in larvae and adult females of Rhipicephalus (Boophilus) microplus and reports the first known evidence for the participation of ABC transporters in IVM resistance in R. microplus.
Journal ArticleDOI

The quest for a universal vaccine against ticks: cross-immunity insights.

TL;DR: Progress towards effective anti-tick vaccines is reviewed in the light of emerging data from studies including heterologous tick challenge, indicating that the decades-long search for a universal tick vaccine is making progress, with such a vaccine likely to be based on multiple cross-reactive antigens.